http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Scholar Rock Reports First Quarter 2021 Financial Results and Highlights Business Progress
-
Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in Therapy
-
Scholar Rock (SRRK) Announces Issuance of U.S. Patent Broadly Relevant to Inhibitors of Myostatin Activation
-
Scholar Rock Announces Issuance of U.S. Patent Broadly Relevant to Inhibitors of Myostatin Activation
-
Scholar Rock Holding Corp. (SRRK) Announces Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial
-
Scholar Rock Presents Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial at the American Association for Cancer Research Annual Meeting
-
Scholar Rock (SRRK) Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 SMA
-
Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
-
Scholar Rock (SRRK) Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of Toxicology
-
Scholar Rock Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of Toxicology
-
Scholar Rock Holding Corp. (SRRK) Announces Addition of Joshua Reed to Its Board of Directors
-
Scholar Rock Announces the Addition of Joshua Reed to Its Board of Directors
-
Scholar Rock (SRRK) Announces Issuance of U.S. Patent Protecting Add-On or Combination Therapy with a Myostatin Inhibitor for the Treatment of SMA
-
Scholar Rock Announces Issuance of U.S. Patent Protecting Add-On or Combination Therapy with a Myostatin Inhibitor for the Treatment of Spinal Muscular Atrophy
-
Scholar Rock Presents TOPAZ Interim Analysis Data for Apitegromab in Spinal Muscular Atrophy at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
-
Scholar Rock Reports Full Year 2020 Financial Results and Highlights Business Progress
-
Scholar Rock Announces Senior Management Promotions
-
Scholar Rock Holding Corp. (SRRK) Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit
-
Scholar Rock Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit
-
Scholar Rock (SRRK) Provides Corporate Update and Highlights Priorities for 2021
-
Scholar Rock Provides Corporate Update and Highlights Priorities for 2021
-
Scholar Rock Reports Third Quarter 2020 Financial Results and Highlights Business Progress
-
Scholar Rock (SRRK) Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 SMA
-
Scholar Rock Announces Positive Proof-of-Concept Data from TOPAZ Phase 2 Trial Interim Analysis of SRK-015 in Patients with Type 2 and Type 3 Spinal Muscular Atrophy
-
Scholar Rock Secures $50 million Debt Facility with Silicon Valley Bank and Oxford Finance
-
Scholar Rock Presents Data for SRK-015 at the World Muscle Society 2020 Virtual Congress
-
Scholar Rock Announces First Patient Dosed in Part A2 of DRAGON Phase 1 Proof-of-Concept Trial of SRK-181 to Overcome Primary Resistance to Anti-PD-(L)1 Therapy
-
Scholar Rock to Present at Upcoming Healthcare Conferences
-
Scholar Rock (SRRK) Announces Issuance of U.S. Patent Providing Composition of Matter Protection for SRK-015
-
Scholar Rock Announces Issuance of U.S. Patent Providing Composition of Matter Protection for SRK-015
-
Scholar Rock Holding Corp. (SRRK) Announces SRK-015 has Received Rare Pediatric Disease Designation from U.S. FDA for Treatment of Spinal Muscular Atrophy
-
Scholar Rock Announces that SRK-015 has Received Rare Pediatric Disease Designation from U.S. FDA for the Treatment of Spinal Muscular Atrophy
-
Scholar Rock Reports Second Quarter 2020 Financial Results and Highlights Business Progress
-
Scholar Rock to Present at the 2020 Wedbush PacGrow Healthcare Conference
-
Scholar Rock to Announce Second Quarter 2020 Financial Results and Introduce Newest Members of Management August 7, 2020
-
Scholar Rock Holding Corp. (SRRK) Names Edward (Ted) Myles as CFO & Head of Business Operations
-
Scholar Rock Appoints Edward (Ted) Myles as Chief Financial Officer and Head of Business Operations
-
Scholar Rock (SRRK) Appoints Tony Kingsley as President and CEO
-
Scholar Rock Appoints Tony Kingsley as President and CEO
-
Scholar Rock to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
-
Scholar Rock Holding Corp. (SRRK) Highlights Clinical and Preclinical Data for SRK-015
-
Scholar Rock Presents Clinical and Preclinical Data for SRK-015 at the 2020 Virtual Cure SMA Research and Clinical Care Meeting
-
Scholar Rock to Present at the Jefferies Virtual Global Healthcare Conference
-
Scholar Rock Holding Corp. (SRRK) Adds Tony Kingsley to Board
-
Scholar Rock Appoints Tony Kingsley to Its Board of Directors
-
Scholar Rock Presents Baseline Demographics Data from the SRK-015 TOPAZ Trial at the American Academy of Neurology Conference
-
Scholar Rock Reports First Quarter 2020 Financial Results and Highlights Business Progress
-
Scholar Rock Holding Corp. (SRRK) Begins Patient Dosing in Phase 1 Proof-of-Concept Immuno-Oncology Trial of SRK-181 to Overcome Primary Resistance to Anti-PD-(L)1 Therapy
-
Scholar Rock Announces Initiation of Patient Dosing in Phase 1 Proof-of-Concept Immuno-Oncology Trial of SRK-181 to Overcome Primary Resistance to Anti-PD-(L)1 Therapy
-
Scholar Rock (SRRK) Announces Issuance of U.S. Patent Broadly Relevant to Antibodies that Modulate TGFβ Activation
